Experimental cell therapy aims to stop deadly transplant complication
NCT ID NCT04328714
Summary
This early-stage study tested whether specially prepared stem cells could safely prevent graft-versus-host disease (GVHD) in patients receiving bone marrow transplants for blood cancers. GVHD is a serious and common complication where the donor's immune cells attack the patient's body. Researchers gave patients these modified cells around the time of transplant to try to calm the immune system and reduce GVHD risk. The study was terminated early after enrolling only 4 participants.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MYELODYSPLASTIC SYNDROMES are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Children's Healthcare of Atlanta at Egleston
Atlanta, Georgia, 30322, United States
-
Emory University
Atlanta, Georgia, 30322, United States
-
Winship Cancer Institute of Emory University
Atlanta, Georgia, 30322, United States
Conditions
Explore the condition pages connected to this study.